Rexahn Pharmaceuticals Announces Positive Top-line Phase IIa Data for Archexin in Patients With Metastatic Pancreatic Cancer

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, Tuesday announced top-line results from a Phase II clinical study of Archexin, its clinical-stage oncology drug candidate.
Yahoo! Finance